Evoke Pharma stock exits after USD 11 cash merger

Evoke Pharma stock completed its corporate exit at USD 11.00 per share after a cash tender offer and merger. The transaction changed EVOK from a listed pharmaceutical company into a wholly owned subsidiary of QOL Medical.

USD 11 cash deal completed

According to Stock Titan, buyers acquired all outstanding Evoke Pharma common shares for USD 11.00 per share on December 16, 2025. The merger became effective on December 17, 2025, when QOL-EOS Merger Sub merged into Evoke Pharma.

The transaction therefore linked two concrete values for shareholders: USD 11.00 in cash per share and the final EVOK quote of USD 11.00 dated December 17, 2025. That one-for-one match marked the conversion of the listed equity into cash consideration rather than a continuing public-market investment.

QOL Medical takes ownership

The merger agreement was dated November 3, 2025, while the tender offer settled on December 16 and the merger followed one day later. Stock Titan reports that Evoke Pharma became a wholly owned subsidiary of QOL Medical after the effective merger date.

The structure also covered employee and executive options. Each outstanding option vested, was canceled, and was converted into a cash right based on the USD 11.00 offer price less its exercise price.

EVOK shares removed

Robinhood lists the corporate action on December 18, 2025 and states that Evoke Pharma shares were removed, with shareholders receiving USD 11.0000 per share in cash. The dated action explains why EVOK no longer represents an ordinary ongoing stock quotation, while the USD 11.00 amount remains the key shareholder value from the transaction.